Inclusion Criteria:  Advanced or metastatic PC (confirmed by the recommended histological and imaging methods). Age ≥ 18 years. Planning to start 1st line chemotherapy with NabG. Eastern Cooperative Group (ECOG) 0-2. Life expectancy >6 months. Written informed consent.  Exclusion Criteria:  Subjects with contraindication to receive anticoagulant:  Any hypersensitivity to anticoagulant or excipients. History of heparin-induced thrombocytopenia type II (HIT II). Active major bleeding or pre-diathesis for major bleeding Septic endocarditis. Creatinine clearance <20 mL/min according to Cockcroft-Gault formula. Platelet count < 50 G/L at inclusion. Hepatic dysfunction defined as at least one of the following: AST and/or ALT > 5 x ULN, bilirubin > 2 x ULN. Recent (< 1 month) oncological surgery, major abdominal or thoracic surgery, major orthopedic surgery, vascular surgery. Recent (< 1 month) acute coronary syndrome or any other arterial thrombosis, thrombotic or hemorrhagic stroke. Patients on chronic anticoagulation or on dual anti-platelet treatment. Pregnancy/lactation or insufficient contraception during the study and up to 3 months after the study. Severe concomitant disease that as per investigator's judgement is not compatible with participation in the study.